Fundamentals of Pharmaceutical Nanoscience

Fundamentals of Pharmaceutical Nanoscience

Hardback

Edited by Ijeoma F. Uchegbu, Edited by Andreas G. Schatzlein, Edited by Woei Ping Cheng, Edited by Aikaterini Lalatsa

$108.82
List price $127.27
You save $18.45 14% off

Free delivery worldwide
Available
Dispatched in 1 business day
When will my order arrive?

  • Publisher: Springer-Verlag New York Inc.
  • Format: Hardback | 612 pages
  • Dimensions: 160mm x 234mm x 38mm | 1,315g
  • Publication date: 9 December 2013
  • Publication City/Country: New York, NY
  • ISBN 10: 1461491630
  • ISBN 13: 9781461491637
  • Edition: 1
  • Edition statement: 2013 ed.
  • Illustrations note: 56 black & white illustrations, 99 colour illustrations, 51 black & white tables, biography
  • Sales rank: 1,391,963

Product description

Nanoscience or the science of the very small offers the pharmaceutical scientist a wealth of opportunities. By fabricating at the nanoscale, it is possible to exert unprecedented control on drug activity. This textbook will showcase a variety of nanosystems working from their design and construction to their application in the field of drug delivery. The book is intended for graduate students in drug delivery, physical and polymer chemistry, and applied pharmaceutical sciences courses that involve fundamental nanoscience. The purpose of the text is to present physicochemical and biomedical properties of synthetic polymers with an emphasis on their application in polymer therapeutics i.e., pharmaceutical nanosystems, drug delivery and biological performance. There are two main objectives of this text. The first is to provide advanced graduate students with knowledge of the principles of nanosystems and polymer science including synthesis, structure, and characterization of solution and solid state properties. The second is to describe the fundamentals of therapeutic applications of polymers in drug delivery, targeting, response modifiers as well as regulatory issues. The courses, often listed as Advanced Drug Delivery and Applied Pharmaceutics; Polymer Therapeutics; or Nanomedicine, are designed as an overview of the field specifically for graduate students in the Department of Pharmaceutical Sciences Graduate Programs. However, the course content may also be of interest for graduate students in related biomedical research programs. These courses generally include a discussion of the major principles of polymer science and fundamental concepts of application of polymers as modern therapeutics. All courses are moving away from the above mentioned course names and going by 'pharmaceutical nanoscience or nanosystems'. This area of research and technology development has attracted tremendous attention during the last two decades and it is expected that it will continue to grow in importance. However, the area is just emerging and courses are limited but they are offered.

Other people who viewed this bought:

Showing items 1 to 10 of 10

Other books in this category

Showing items 1 to 11 of 11
Categories:

Author information

Professor Ijeoma F. Uchegbu Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at the UCL School of Pharmacy, University College London and Chief Scientific Officer of Nanomerics, a spin out company from the UCL School of Pharmacy in London. She obtained her PhD from the School of Pharmacy, University of London in 1994, was appointed to a lectureship within the Department of Pharmaceutical Sciences, Strathclyde University in 1997 and a Chair in Drug Delivery at Strathclyde University in 2002. In 2006 Ijeoma was appointed to the Chair in Pharmaceutical Nanoscience at the School of Pharmacy and in 2010 Ijeoma founded Nanomerics with Andreas G. Schatzlein. Nanomerics is a speciality pharmaceutical company focused on exploiting pharmaceutical nanotechnology platforms (http://www.nanomerics.com/) for medicines development. Ijeoma's research in pharmaceutical nanoscience has provided insights into nanoparticle design for drug delivery, producing nanosystems (nanomedicines) that promote oral drug absorption, peptide drug transport to the brain and, in collaboration with Andreas Schatzlein, gene/ siRNA transport to experimental tumours. Ijeoma is the former Scientific Secretary of the Controlled Release Society (CRS), a learned society with over 2,000 members, with interests in the delivery of pharmaceuticals, former Chair of the Academy of Pharmaceutical Sciences of Great Britain and the former Academia Expert on the Department for Business Innovation and Skills' Science Engineering and Technology Strategy for Women Expert Group. Ijeoma has been awarded various prizes for her work, notably the UK Department for Business Innovation Skills' Women of Outstanding Achievement in Science Engineering and Technology award (http://www.theukrc.org/women/women-of-outstanding-achievement/2007-collection/professor-ijeoma-uchegbu) and the Royal Pharmaceutical Society's Pharmaceutical Scientist of the Year 2012 and she was elected to the Controlled Release Society College of Fellows in 2013. Ijeoma is the editor of two books, a named inventor on 10 granted patents and 11 patent families. Ijeoma has also authored over 90 peer reviewed journal articles and book chapters. Dr Andreas G. Schatzlein Andreas Schatzlein has a track record of medicines development and translational research in industry and academia. His research interests focus on the discovery and preclinical/clinical development of targeted anti-cancer drugs and nanomedicines and the understanding of their underlying biology. Andreas is a veterinary surgeon by training and, after completion of his doctorate on transdermal nanomedicines delivery, joined the biotech start-up IDEA in Munich to develop this technology commercially. In 1996 joined academia at the Cancer Research UK Beatson Laboratories at the University of Glasgow where became leader of the Experimental Therapeutics and Gene Medicines Group. There he was also responsible for setting up a unit that carried out analysis of pharmacokinetics and pharmacodynamics readouts from early phase translational oncology/nanomedicines trials using a good clinical laboratory practice framework. He currently is a Reader at the UCL School of Pharmacy and co-founder and CEO of Nanomerics Ltd, a UCL spinout company developing pharmaceutical nanotechnology. Dr Woei Ping Cheng Woei Ping Cheng joined the School of Pharmacy at University of Hertfordshire, UK as a senior lecturer in pharmaceutics in January 2009. Prior to obtaining her PhD in 2005, she was a lecturer at the School of Pharmacy and Life Sciences, The Robert Gordon University, UK. She obtained her first class BSc (Hons) Pharmacy and PhD from University of Strathclyde. Her research interest is in the use of novel self-assembling polymers for the delivery of challenging therapeutic agents such as hydrophobic drugs, proteins and siRNA. She is the editorial board member of Drug Delivery Letters and chair person of UK-Ireland Controlled Release Society (UKICRS). She had been invited to chair and speak in a number of national and international scientific conferences and has published more than 35 peer-reviewed papers and conference abstracts, 3 patents and one book chapter. Her research is supported by industry, charity and UK research council. Dr Aikaterini Lalatsa Aikaterini Lalatsa is a Lecturer in Pharmaceutics and Drug Delivery, in the Department of Pharmacy, University of Hertfordshire working in development of oral nanomedicinal formulations utilizing biodegradable polymers and lipids. Her research interests include engineering, synthesis, characterization, and preclinical evaluation of novel nanocarriers for brain delivery of APIs and biomacromolecules, peptide delivery utilizing non-invasive routes and oral delivery of poorly soluble drugs. Aikaterini has worked as a research fellow in University of Patra on an FP7 project (Nanoparticles for Therapy and Diagnosis of Alzheimer Disease project) and in School of Pharmacy, University of London (UCL School of Pharmacy) on a EPSRC-GSK funded project with aim to translate patented platform technology that stemmed out her PhD work into an oral peptide nanomedicine. Aikaterini is a registered pharmacist in the UK and Greece and has obtained her PhD in degree in 2009 at the School of Pharmacy, University of London on oral nanoparticulate peptide delivery to the brain.

Back cover copy

The emerging discipline of nanoscience has resulted in a number of new technologies. These groundbreaking advances are firing the imagination of a generation of scientists and leading to new materials with a wealth of functionality. In the biomedical sciences these technological advances are finally translating into clinically relevant products and bringing patients exciting new therapies and diagnostics. This is the first book of its kind that seeks to present the application of nanoscience to medicines development - pharmaceutical nanoscience in one accessible volume. The nanotechnologies that derive from pharmaceutical nanoscience are just beginning to make their mark. The book spans the chemistries, which are harnessed to create the materials, the concepts upon which their application rests and model examples of the exploitation of this new knowledge to bring healthcare benefits. A final chapter on the commercialisation pathways taken by these new technologies provides a fitting end to the book as all science is geared towards new knowledge or an improved quality of life through the creation of new interventions, products or services. The book is designed to introduce undergraduates to the technologies underpinning these emerging and existing products, provide a reference volume for graduate scholars seeking an introduction to the fields of pharmaceutical nanoscience and pharmaceutical nanotechnology and provide the expert with accessible information on complementary areas satellite to their main areas of expertise."Professor Ijeoma F. Uchegbu"Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at the UCL School of Pharmacy, University College London and Chief Scientific Officer of Nanomerics, a spin out company from the UCL School of Pharmacy in London. She obtained her PhD from the School of Pharmacy, University of London in 1994, was appointed to a lectureship within the Department of Pharmaceutical Sciences, Strathclyde University in 1997 and a Chair in Drug Delivery at Strathclyde University in 2002. In 2006 Ijeoma was appointed to the Chair in Pharmaceutical Nanoscience at the School of Pharmacy and in 2010 Ijeoma founded Nanomerics with Andreas G. Schatzlein. Nanomerics is a speciality pharmaceutical company focused on exploiting pharmaceutical nanotechnology platforms (http: //www.nanomerics.com/) for medicines development. Ijeoma s research in pharmaceutical nanoscience has provided insights into nanoparticle design for drug delivery, producing nanosystems (nanomedicines) that promote oral drug absorption, peptide drug transport to the brain and, in collaboration with Andreas Schatzlein, gene/ siRNA transport to experimental tumours. Ijeoma is the former Scientific Secretary of the Controlled Release Society (CRS), a learned society with over 2,000 members, with interests in the delivery of pharmaceuticals, former Chair of the "Academy of Pharmaceutical Sciences of Great Britain" and the former Academia Expert on the Department for Business Innovation and Skills "Science Engineering and Technology Strategy for Women Expert Group." Ijeoma has been awarded various prizes for her work, notably the UK Department for Business Innovation Skills "Women of Outstanding Achievement in Science Engineering and Technology" award (http: //www.theukrc.org/women/women-of-outstanding-achievement/2007-collection/professor-ijeoma-uchegbu) and the "Royal Pharmaceutical Society s Pharmaceutical Scientist of the Year 2012" and she was elected to the Controlled Release Society College of Fellows in 2013.Ijeoma is the editor of two books, a named inventor on 10 granted patents and 11 patent families. Ijeoma has also authored over 90 peer reviewed journal articles and book chapters."Dr Andreas G. Schatzlein" Andreas Schatzlein has a track record of medicines development and translational research in industry and academia. His research interests focus on the discovery and preclinical/clinical development of targeted anti-cancer drugs and nanomedicines and the understanding of their underlying biology. Andreas is a veterinary surgeon by training and, after completion of his doctorate on transdermal nanomedicines delivery, joined the biotech start-up IDEA in Munich to develop this technology commercially.In 1996 joined academia at the Cancer Research UK Beatson Laboratories at the University of Glasgow where became leader of the Experimental Therapeutics and Gene Medicines Group. There he was also responsible for setting up a unit that carried out analysis of pharmacokinetics and pharmacodynamics readouts from early phase translational oncology/nanomedicines trials using a good clinical laboratory practice framework. He currently is a Reader at the UCL School of Pharmacy and co-founder and CEO of Nanomerics Ltd, a UCL spinout company developing pharmaceutical nanotechnology."Dr Woei Ping Cheng "Woei Ping Cheng joined the School of Pharmacy at University of Hertfordshire, UK as a senior lecturer in pharmaceutics in January 2009. Prior to obtaining her PhD in 2005, she was a lecturer at the School of Pharmacy and Life Sciences, The Robert Gordon University, UK. She obtained her first class BSc (Hons) Pharmacy and PhD from University of Strathclyde. Her research interest is in the use of novel self-assembling polymers for the delivery of challenging therapeutic agents such as hydrophobic drugs, proteins and siRNA. She is the editorial board member of Drug Delivery Letters and chair person of UK-Ireland Controlled Release Society (UKICRS). She had been invited to chair and speak in a number of national and international scientific conferences and has published more than 35 peer-reviewed papers and conference abstracts, 3 patents and one book chapter. Her research is supported by industry, charity and UK research council. "Dr Aikaterini Lalatsa"Aikaterini Lalatsa is a Lecturer in Pharmaceutics and Drug Delivery, in the Department of Pharmacy, University of Hertfordshire working in development of oral nanomedicinal formulations utilizing biodegradable polymers and lipids. Her research interests include engineering, synthesis, characterization, and preclinical evaluation of novel nanocarriers for brain delivery of APIs and biomacromolecules, peptide delivery utilizing non-invasive routes and oral delivery of poorly soluble drugs. Aikaterini has worked as a research fellow in University of Patra on an FP7 project (Nanoparticles for Therapy and Diagnosis of Alzheimer Disease project) and in School of Pharmacy, University of London (UCL School of Pharmacy) on a EPSRC-GSK funded project with aim to translate patented platform technology that stemmed out her PhD work into an oral peptide nanomedicine. Aikaterini is a registered pharmacist in the UK and Greece and has obtained her PhD in degree in 2009 at the School of Pharmacy, University of London on oral nanoparticulate peptide delivery to the brain. "

Table of contents

1. Introduction Ijeoma Uchegbu Part 1 - Nanomaterials Fabrication, Characterisation and Use These chapters will focus on the fabrication and characterisation of the various nanomaterials. Each chapter will address the following headings: Materials Chemistry, Nanoparticle Synthesis, Nanoparticle Physical Characterisation, and Application of Nanoparticles. 2. Low Molecular Weight Micelles Ijeoma Uchegbu 3. Liposomes Marcel Bally 4. Niosomes Maria Carafa 5. Solid Lipid Nanoparticles Eliana B. Souto, Joana F. Fangueiro, Rainer H. Muller 6. Nanoemulsions Maria de La Fuente 7. Polymer Drug Conjugates Francesca Greco 8. Polymersomes Dennis Discher 9. Polymeric Nanoparticles Ijeoma Uchegbu 10. Porous Silicon Nanoparticles Helder Almeida Santos 11. Drug Nanocrystals Leena Peltonen Part 2 - Concepts Underpinning the Application of Biomedical Nanomaterials These chapters will focus on the concepts underpinning the application of nanomaterials to various biomedical areas and will outline the key advantages that nanomaterials are able to offer pharmaceuticals and diagnostics, with appropriate examples. Chapter headings will be: Clinical need, technologies, preclinical proof of concept, clinical experience. 12. Biological Barriers: Transdermal, Oral, Mucosal, Blood Brain Barrier and the Blood Eye Barrier Andreas Schatzlein 13. Active targeting Aikaterini Lalatsa 14. Drug Solubilisation (WPC) Woei Ping Cheng Part 3 - Therapeutic and Diagnostic Applications These chapters will focus on the therapeutics that have emerged from the nanomaterials and an exploitation of the concepts outlined in Part 2 and will include the clinical experience wherever possible. Apart from the last chapter - chapter headings will be as follows: disease pathology, conventional therapies, nano-enabled therapies, pre-clinical proof of concept, clinical experience. 15. Cancer Chemotherapy (IFU) Hiroshi Maeda 16. Vaccines Yvonne Perrie 17. Antiinfectives Steve Brocchini 18. Gene and SiRNA Therapy Ijeoma F. Uchegbu 19. Peptides, Proteins and Antibodies Aikaterini Lalatsa 20. Imaging Andreas G. Schatzlein 21. Commercial Exploitation of Pharmaceutical Nanotechnology Gregor Cevc